MedPath

Esaxerenone

Generic Name
Esaxerenone
Drug Type
Small Molecule
Chemical Formula
C22H21F3N2O4S
CAS Number
1632006-28-0
Unique Ingredient Identifier
N62TGJ04A1

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background

Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).

Indication

用于治疗高血压等。

Clinical Trials
Related News

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Phase 1
Completed
Conditions
Mineralocorticoid Receptor Antagonist
Hypertension
Interventions
Drug: Placebo matching CS-3150
First Posted Date
2019-07-15
Last Posted Date
2019-07-15
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
55
Registration Number
NCT04019652
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

Study of CS-3150 in Patients With Essential Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
First Posted Date
2016-09-07
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
1001
Registration Number
NCT02890173

Study of CS-3150 in Patients With Primary Aldosteronism

Not Applicable
Completed
Conditions
Primary Aldosteronism
Interventions
First Posted Date
2016-08-31
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
44
Registration Number
NCT02885662
Locations
🇯🇵

Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Not Applicable
Completed
Conditions
Essential Hypertension
Interventions
First Posted Date
2016-07-28
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
40
Registration Number
NCT02848170

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Phase 3
Completed
Conditions
Hypertension
Interventions
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
51
Registration Number
NCT02807974

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

Phase 3
Completed
Conditions
Hypertension With Moderate Renal Impairment
Interventions
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
58
Registration Number
NCT02807987

Study of CS-3150 in Patients With Severe Hypertension

Phase 3
Completed
Conditions
Severe Hypertension
Interventions
First Posted Date
2016-06-21
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
20
Registration Number
NCT02808026

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
First Posted Date
2016-03-29
Last Posted Date
2019-10-08
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Target Recruit Count
368
Registration Number
NCT02722265

A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment

Phase 2
Completed
Conditions
Hypertension
Interventions
First Posted Date
2015-05-19
Last Posted Date
2019-10-08
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
33
Registration Number
NCT02448628

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Phase 2
Completed
Conditions
Diabetic Nephropathy
Interventions
Drug: placebo
First Posted Date
2015-01-26
Last Posted Date
2018-12-21
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
365
Registration Number
NCT02345057
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy